clinical trial · NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Vertex Pharmaceuticals Incorporated·phase2·recruiting·n = 30
Myasthenia Gravis, GeneralizedPovetaciceptPlacebo
brief summary
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
started
Apr 16, 2026
primary completion
Mar 2, 2029
completion
Mar 2, 2029
last updated
Apr 21, 2026
official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol